Accessing Targeted Nanoparticles to the Brain: The Vascular Route

Author(s): A. Burkhart, M. Azizi, M.S. Thomsen, L.B. Thomsen, T. Moos

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 36 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


The blood-brain barrier (BBB), formed by brain capillary endothelial cells, prevents the entry of several drug molecules to the brain, especially molecules hydrophilic in nature. Advanced drug carriers like nanoparticles share the potential to allow entry of therapeutic proteins and genetic molecules into the central nervous system (CNS). Taking a targeting approach by conjugating molecules acting as ligands or monoclonal antibodies with affinity for proteins expressed on the luminal side of brain capillary endothelial cells, the nanoparticles can be designed to enable transport into the brain endothelium, or perhaps even through the endothelium leading to blood to brain transport. Currently, the iron-binding protein transferrin or antibodies raised against the transferrin receptor denote the most feasible molecule for targeting purposes at the BBB. This manuscript reviews the targetability of nanoparticles to the brain capillary endothelial cells, how nanocarriers may enter and transfer through the brain endothelium, and how likely restraints denoted by the threedimensional mesh of the extracellular proteins forming the brain capillary basement membrane challenge the possibilities for enabling transport of large molecules through the BBB encapsulated in nanoparticles.

Keywords: Basement membrane, blood-brain barrier, endocytosis, nanoparticle, neurodegeneration, OX26, transcytosis, transferrin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [4092 - 4099]
Pages: 8
DOI: 10.2174/0929867321666140716095317
Price: $65

Article Metrics

PDF: 37